SCHEMBL2620463

SCHEMBL2620463

COC(=O)[C@H](CC(C)C)NC(=O)[C@]12CC[C@@H](C(C)C)[C@@H]1[C@H]1CC[C@@H]3[C@@]4(C)CCC(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2

nearest known ligand 0.52

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 10/20 0.51
▸ LMNA P02545 1/20 0.51
▸ NT5E P21589 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ NR1H4 Q96RI1 9/20 0.50
▸ PRKCD Q05655 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Methyl Dihydrobetulonate SCHEMBL13747683 0.85 GPBAR1 (0.58) GPBAR1LMNANT5ESMN1; SMN2NR1H4
Dihydrobetulonic Acid SCHEMBL3276418 0.83 GPBAR1 (0.71) GPBAR1LMNANT5ESMN1; SMN2PRKCD
Dihydrobetulonic Acid SCHEMBL13908784 0.83 GPBAR1 (0.71) GPBAR1LMNANT5ESMN1; SMN2PRKCD
Dihydrobetulonic Acid SCHEMBL10061167 0.83 GPBAR1 (0.71) GPBAR1LMNANT5ESMN1; SMN2PRKCD
Dihydrobetulonic Acid SCHEMBL14414141 0.83 GPBAR1 (0.71) GPBAR1LMNANT5ESMN1; SMN2PRKCD
SCHEMBL10061168 0.82 GPBAR1 (0.59) GPBAR1LMNANT5ESMN1; SMN2NR1H4
SCHEMBL16511700 0.82 GPBAR1 (0.59) GPBAR1LMNANT5ESMN1; SMN2NR1H4
SCHEMBL9891261 0.81 GPBAR1 (0.57) GPBAR1LMNANT5ESMN1; SMN2NR1H4
SCHEMBL13908786 0.81 GPBAR1 (0.55) GPBAR1LMNANT5ESMN1; SMN2NR1H4
SCHEMBL13908792 0.81 GPBAR1 (0.55) GPBAR1LMNANT5ESMN1; SMN2NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120101098-A1 3,28-DISUBSTITUTED BETULINIC ACID DERIVATIVES AS ANTI-HIV AGENTS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-04-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101098-A1 3,28-DISUBSTITUTED BETULINIC ACID DERIVATIVES AS ANTI-HIV AGENTS BET1, CD4, PGGT1B GPBAR1 713/4885LMNA 2803/4885NT5E 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback